UroGen (URGN) - Market Capitalization to Book Value Ratio

Corporate emblem and logo of UroGen (URGN)

The market trend for UroGen Pharma Ltd. (URGN) reflects the dynamics of an asset currently valued at -12.40. The business relies on the exclusive RTGel technology, which enables the non-invasive treatment of renal neoplasms. However, global conflicts are hindering cross-border clinical trials and disrupting the logistics of biomaterials. Meanwhile, production capacities are operating steadily, with equipment being continuously upgraded to maintain total sterility in the manufacturing of urological products.

UroGen Pharma Ltd. (URGN) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company UroGen Pharma Ltd (URGN)

- market value and analyst target forecast:
Price Chart UroGen Pharma Ltd.|URGN - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization UroGen|URGN - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share UroGen Pharma|URGN - Book Capitalization|Market Value to Book Value Ratio urogen.com|URGN - Total Business Assets
- debt and liquidity details:
Total Debt to Capital UroGen Pharma Ltd.|URGN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital UroGen|URGN - Company Cumulative Debt|Debt to Book Capitalization Ratio UroGen|URGN - Company Long-Term Loans and Borrowings|Company Current Liabilities UroGen Pharma|Quick Ratio urogen.com
- earnings and valuation multiples indicators:
URGN - Net Income
Comprehensive company analysis:UroGen Pharma Ltd.
Flagship merchandise of UroGen Pharma Ltd

Effective diversification of logistics chains for UroGen Pharma Ltd. (URGN) oncology drug supplies ensures operational stability and the preservation of tangible assets. By analyzing this P/B ratio chart, investors can assess the market value premium over book value, allowing them to identify overvalued quotes and determine the price safety margin relative to the business's intrinsic value under current market conditions.

Who UroGen Pharma Ltd. competes with

BeiGene Ltd (ONC) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio HALO|RVMD (Revolution Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Ascentage Pharma Group International (AAPG)|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio Bicara Corp (BCAX)|Market Value to Book Value Ratio Personalis, Inc. PSNL|ERAS: Capitalization to Book Value Ratio|Delcath Systems - Market Capitalization to Book Value Ratio|Y-mAbs Therapeutics Inc (YMAB) - Market Cap to Net Assets Ratio|AURA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Candel Therapeutics, Inc. (CADL)|Market Value to Book Value Ratio Accuray Incorporated|SLS: Market Value to Book Value|Market Cap to Net Assets Ratio ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio HURA (TuHURA Biosciences)|TARA - Market Cap to Net Assets Ratio|FATE: Market Cap to Net Assets Ratio|WHWK - Market Capitalization to Book Value Ratio|tscan.com (TCRX) - Market Value to Book Value Ratio|Champions Oncology, Inc. - Market Value to Book Value|XBIT (XBiotech Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CEL-SCI Corp CVM|Market Cap to Net Assets Ratio OSTX (OS Therapies Incorporated)|Market Capitalization to Book Value Ratio Radiopharm Theranostics Ltd (RADX)|Market Value to Book Value Ratio Artiva Biotherapeutics ARTV|Market Value to Book Value ANL|VERU - Market Value to Book Value Ratio|Market-to-Book Ratio Tempest Therapeutics Corp|XLO: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Renovaro RENB|MURA (Mural Oncology PLC) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Kairos Pharma Inc KAPA|Market Value to Book Value Ratio OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg - Capitalization to Book Value Ratio|Curis - Market Cap to Net Assets Ratio|Market Value to Book Value APLM|THAR - Market Value to Book Value Ratio|Market Capitalization to Net Assets ADVB|GNPX: Market Capitalization to Book Value Ratio|Calidi Biotherapeutics, Inc. - Market Value to Book Value|SBFM (Sunshine Biopharma) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Xenetic Bio|Market Value to Book Value Ratio Salarius Pharmaceuticals, Inc. (SLRX)|PPBT (Purple Biotech Ltd) - Market Value to Book Value|Market Value to Book Value Ratio American Oncology Network, Inc. AONC|BGNE - Market Cap to Net Assets Ratio|Checkpoint Therapeutics - Market Capitalization to Book Value Ratio|ELEV - Market Capitalization to Book Value Ratio|ICAD (icadmed.com) - Market Cap to Net Assets Ratio|Ikena Oncology - Market Value to Book Value|Market Value to Book Value Ratio Notable Labs Inc.|Market Value to Book Value Ratio VIRX|Market Cap to Net Assets Ratio MOR (MorphoSys AG)|Market Cap to Book Value Multiple NAYA|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)